4Fehmann HC,Habener JF.Insulinotripic hormone glucagon-like peptide-1(7-37)stimulation of proinsulin gene expression and proinsulin biosynin insulinoma β TC-1 cell[J].Endocrinology,1992,130(4):159
5Kieffer TJ.Gastro-intestinal hormones GLP and GLP-1[J].Ann Endocrinol,2004,65(1):13
6Hoist JJ.Glucagon-like peptide 1(GLP-1):An intestinal hormone,signaling nutritional abundance with an urnusual therapeutic potential[J].Trends Endocrinol Metab,1999,10(6):229
7Gomez E,Pritchard C,Herbert TP.cAMP-dependent protein kinase and Ca^2+ influx through L-type voltage-gated calcium channels mediate raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β-cells[J].Biol Chem,2002,277(50):48 146
8Gutniak MK,Linde B,Holst JJ,et al.Subcutaneous injection of the incretin hormone glucagons-like peptide 1 abolishes postprandial glycemia in NIDDM[J].Diabetes Care,1994,17(9):1 039
9Nauck MA,Wollschlager D,Wermer J,et al.Effects of subcutaneous GLP-1[7-36 amide] in NIDDM[J].Diabetologia,1996,39(12):1 546
10Briones M,Bajaj M.Exenatide:a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus[J].Expert Opin Pharmacother,2006,7(8):1 055
二级参考文献15
1Ebeling P, Jansson P A, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin[J]. Diabetes Care, 1997,20 : 1287-1289.
2Rosskamp R H, Park G. Long-acting insulin analogs[J].Diabetes Care,1999, 22(Suppl 2) :B109-B113.
3Vajo Z, Fawcett J, Duckworth W C. Recombinant DNA technology in the treatment of diabetes [ J]. Endocr Rev, 2001,22:706-717.
4McKeage K, Goa K L. Insulin Glargine [ J ]. Drugs, 2001,61 :1599-1624.
5Heinemann L, Linkeschova R, Rave K. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000,23 : 644-649.
6Talaulicar M, Willms B, Rosskamp R. HOE901, ein neues insulin analog zur substitution des basalen insulin-bedarfs bei type 1 diabetes[ J ]. Diabetes Stoffwechsel, 1996,5 : 3-6.
7Ratner R E, Hirsch I B, Neifing J L. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes[J]. Diabetes Care ,2000,23 : 639-643.
8Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes [ J ] .Diabetes Care,2000,23 : 1130-1136.
9Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose(FBG) and less symptomatic hypoglycemia with QD insulin glargine(Lautus) compare to bid NPH insulin in subjects with type 1 diabetes[J]. Diabetes,2001,50( Suppl 2) :116-117.
10Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine compared to bedtime NPH insulin in patients with type 2 diabetes [ J] . Diabetes, 2001,50(Suppl 2) : 112-113.
7Fire A, Xu S, Momgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature, 1998, 391 (6 669) :806.
8Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis[J]. Nat Med, 2003,9(3) :347.
